Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28684483 | 0.98 | SLC6A2 (0.36) | SLC6A2HTR1ASSTR4 | |
| SCHEMBL1287870 | 0.87 | SLC6A2 (0.37) | SLC6A2HTR1ASSTR4 | |
| SCHEMBL22265190 | 0.83 | SLC6A2 (0.36) | SLC6A2HTR1ASSTR4 | |
| SCHEMBL12504907 | 0.82 | SLC6A2 (0.39) | SLC6A2HTR1ASSTR4 | |
| SCHEMBL19366757 | 0.82 | SLC6A2 (0.39) | SLC6A2HTR1ASSTR4 | |
| SCHEMBL17340716 | 0.82 | SLC6A2 (0.39) | SLC6A2HTR1A | |
| SCHEMBL17409968 | 0.82 | SLC6A2 (0.39) | SLC6A2HTR1ASSTR4 | |
| SCHEMBL627761 | 0.82 | SLC6A2 (0.39) | SLC6A2HTR1ASSTR4 | |
| SCHEMBL12275915 | 0.82 | SLC6A2 (0.39) | SLC6A2HTR1A | |
| SCHEMBL17340694 | 0.82 | SLC6A2 (0.39) | SLC6A2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2020198058-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | SLC6A2 4424/4885HTR1A 2632/4885SSTR4 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.